Could This Implant Be the New Weapon Against Opioid, Heroin Addiction?

Miami Herald, May 24, 2016. The U.S. Food and Drug Administration is expected to decide this week whether to approve a new weapon in the war against heroin and prescription opioid addiction. The Probuphine implant by Braeburn Pharmaceuticals of Princeton, NJ, would be the first FDA-approved implant for opioid dependence and the longest-acting treatment to address the growing problem.

Read More »

US Healthcare: Power to the Patients?

Financial Times, May 22, 2016. Families of boys suffering from Duchenne muscular dystrophy push for approval of a new medicine because there are no other treatments. But scientists point out that there is no evidence that the drug works. Does it set a dangerous precedent for FDA to approve a new drug based on patients’ claims rather than science?

Read More »

Why We Shouldn’t Trade a Weakened FDA for More Medical Research Funds

STAT, May 17, 2016. There is no question that more research funding is necessary and that finding legitimate ways to get medicines to patients faster is crucial. But Congress ought to separate the debate over research funding from the rest of the legislation. Loosening regulatory standards would only create problems for which real cures will be needed.

Read More »

Experts Decry Tying Medical Research Funds to FDA Standards Changes

Wall Street Journal, May 12, 2016. Moves in Congress to link billions of dollars in new medical research funding to revised standards for drug and medical-device approvals are troubling some public-health experts, who say the combination makes it too easy for lawmakers to support lower patient-safety standards.

Read More »